Brokers Set Expectations for Heron Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:HRTX)

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Stock analysts at Capital One Financial issued their Q1 2024 earnings per share estimates for Heron Therapeutics in a research report issued on Tuesday, April 23rd. Capital One Financial analyst T. Chiang anticipates that the biotechnology company will post earnings per share of ($0.09) for the quarter. Capital One Financial has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.24) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.28) EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.16 EPS, FY2027 earnings at $0.33 EPS and FY2028 earnings at $0.47 EPS.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.08. The company had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million.

A number of other research analysts have also recently issued reports on HRTX. StockNews.com raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Needham & Company LLC reissued a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a report on Thursday, April 11th.

Heron Therapeutics Stock Performance

Shares of NASDAQ HRTX opened at $2.45 on Thursday. The stock has a market cap of $368.31 million, a PE ratio of -2.85 and a beta of 1.68. The business has a fifty day moving average of $2.74 and a two-hundred day moving average of $1.97. Heron Therapeutics has a 52-week low of $0.50 and a 52-week high of $3.22.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in shares of Heron Therapeutics in the third quarter valued at about $31,000. Victory Capital Management Inc. raised its holdings in shares of Heron Therapeutics by 30.2% in the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 4,617 shares during the last quarter. ACT Advisors LLC. bought a new position in shares of Heron Therapeutics in the fourth quarter valued at about $38,000. Dakota Wealth Management bought a new position in shares of Heron Therapeutics in the third quarter valued at about $55,000. Finally, Diversified Trust Co bought a new position in shares of Heron Therapeutics in the first quarter valued at about $66,000. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.